Overview
Investor Relations Overview
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.
Corporate Presentation
Recent News
- Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
- Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
- Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development